



STATE OF IOWA

CHESTER J. CULVER, GOVERNOR
PATTY JUDGE, LT. GOVERNOR

DEPARTMENT OF HUMAN SERVICES
CHARLES J. KROGMEIER, DIRECTOR

Iowa Medicaid Drug Utilization Review (DUR) Commission Meeting August 4, 2010

**Location: Learning Resource Center
Community Room
3550 Mills Civic Parkway
West Des Moines, Iowa**

Time: 9:30 a.m. – 1:30 p.m.

Final Agenda

1. Welcome & Introductions
 - a) Commission Members and Staff
 - b) Approval of the minutes
2. Commission Business
 - a) Annual Completion of Conflict of Interest Disclosure, Business Associates Agreement, and Confidentiality Update
 - b) Annual DUR Commission Chairperson and Vice Chairperson Elections
 - c) Conflict of Interest Disclosure for Specialists
3. Iowa Medicaid Enterprise Update(s)
4. Quarterly Management Report Summary
5. Case Studies
6. Public Comment (See Conflict of Interest Disclosure Form)
7. Prior Authorization
 - a) Smoking Cessation Therapy – Amend to add nicotine lozenges and nasal spray
 - b) Dalfampridine (*Ampyra*) – Initial Review
 - c) Sodium Oxybate (*Xyrem*) – Initial Review
 - d) Biologicals for Arthritis – Initial Review
 - e) Modified Formulations – Initial Review
 - f) Extended Release Formulations – Second Review
 - g) Biologicals for Ankylosing Spondylitis – Second Review
 - h) Biologicals for Inflammatory Bowel Disease – Second Review
 - i) Biologicals for Plaque Psoriasis – Second Review
 - j) Lidocaine Patch – Criteria Clarification/Second Review

- k) Palivizumab (*Synagis*) – Criteria Review
- 8. ProDUR Edits
 - a) Refill Tolerance – Initial Review
 - b) Quantity Limits Effective October 18, 2010
- 9. Public Comment (See Conflict of Interest Disclosure Form)
- 10. Focus Studies/Provider Education Initiatives
 - a) Long Term Use of Clopidogrel – Initial Review
 - b) Long Term Antibiotic Use and Monitoring – Initial Review
 - c) Atrial Fibrillation and Warfarin Utilization – Initial Review
 - d) Utilization of ACE, ARB, and/or Beta Blocker in CHF - Updated
- 11. Miscellaneous
 - a) DUR Digest – Initial Review
 - b) SMAC Update
 - c) MedWatch
- 12. Executive Closed Session
 - a) Approval of Minutes
 - b) Member Profiles
- 12. Adjournment

Individuals attending meetings of the DUR Commission shall have an opportunity to address the Commission. This opportunity will be granted twice during the open portion of the meeting. In order to accommodate all interested parties, all speakers are requested to limit their comments to **5 minutes or less**. If you represent a drug manufacturer as an employee, as a contractor, as a member of the manufacturer's Speaker Bureau, or by any other means, we expect you to cover your individual product or entire product line in that five-minute time frame. Speakers who represent multiple manufacturers will share their 5 minutes with the other manufacturer representative(s) whose product they are speaking on.

www.iadur.org

For more information contact the DUR Project Coordinator, Pam Smith, R.Ph., at info@iadur.org or (515) 725-1287